Dr. Ramzi Abboud, M.D.
Claim this profileWashington University School of Medicine
Studies Acute Myelogenous Leukemia
Studies Acute Myeloid Leukemia
12 reported clinical trials
30 drugs studied
Area of expertise
1Acute Myelogenous Leukemia
HLA-A negative
HLA-A positive
HLA positive
2Acute Myeloid Leukemia
HLA-A negative
HLA-A positive
HLA positive
Affiliated Hospitals
Clinical Trials Ramzi Abboud, M.D. is currently running
Venetoclax + HMA
for Acute Myeloid Leukemia
This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed into DNA and leads to the activation of cancer suppressor genes, which are genes that help control cell growth. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Gilteritinib is in a class of medications called kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply. This study may help doctors find out if these different approaches are better than the usual approaches. To decide if they are better, the study doctors are looking to see if the study drugs lead to a higher percentage of patients achieving a deeper remission compared to the usual approach.
Recruiting1 award Phase 27 criteria
Novel Therapies
for Acute Myeloid Leukemia
This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin and cytarabine liposome alone; 2) cytarabine and daunorubicin with venetoclax; 3) azacitidine and venetoclax; 4) daunorubicin and cytarabine liposome and venetoclax. "High-risk" refers to traits that have been known to make the AML harder to treat. Cytarabine is in a class of medications called antimetabolites. It works by slowing or stopping the growth of cancer cells in the body. Daunorubicin is in a class of medications called anthracyclines. It also works by slowing or stopping the growth of cancer cells in the body. Azacitidine is in a class of medications called demethylation agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. There is evidence that these newer experimental treatment regimens may work better in getting rid of more AML compared to the standard approach of cytarabine and daunorubicin.
Recruiting1 award Phase 217 criteria
More about Ramzi Abboud, M.D.
Clinical Trial Related4 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Ramzi Abboud, M.D. has experience with
- Fludarabine
- Cyclophosphamide
- Venetoclax
- Azacitidine
- Tacrolimus
- Mycophenolate Mofetil
Breakdown of trials Ramzi Abboud, M.D. has run
Acute Myelogenous Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Acute Lymphoblastic Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Ramzi Abboud, M.D. specialize in?
Ramzi Abboud, M.D. focuses on Acute Myelogenous Leukemia and Acute Myeloid Leukemia. In particular, much of their work with Acute Myelogenous Leukemia has involved HLA-A negative patients, or patients who are HLA-A positive.
Is Ramzi Abboud, M.D. currently recruiting for clinical trials?
Yes, Ramzi Abboud, M.D. is currently recruiting for 7 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Ramzi Abboud, M.D. has studied deeply?
Yes, Ramzi Abboud, M.D. has studied treatments such as Fludarabine, Cyclophosphamide, Venetoclax.
What is the best way to schedule an appointment with Ramzi Abboud, M.D.?
Apply for one of the trials that Ramzi Abboud, M.D. is conducting.
What is the office address of Ramzi Abboud, M.D.?
The office of Ramzi Abboud, M.D. is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.